MRUS vs. BHC, MLTX, MRVI, FOLD, RNA, MOR, JANX, TGTX, RYTM, and DYN
Should you be buying Merus stock or one of its competitors? The main competitors of Merus include Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), Maravai LifeSciences (MRVI), Amicus Therapeutics (FOLD), Avidity Biosciences (RNA), MorphoSys (MOR), Janux Therapeutics (JANX), TG Therapeutics (TGTX), Rhythm Pharmaceuticals (RYTM), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and Merus (NASDAQ:MRUS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
78.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 4.6% of Merus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Merus had 7 more articles in the media than Bausch Health Companies. MarketBeat recorded 12 mentions for Merus and 5 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 0.60 beat Merus' score of 0.19 indicating that Merus is being referred to more favorably in the news media.
Merus has lower revenue, but higher earnings than Bausch Health Companies. Merus is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Bausch Health Companies presently has a consensus target price of $11.33, indicating a potential upside of 67.41%. Merus has a consensus target price of $56.33, indicating a potential upside of 28.29%. Given Merus' higher possible upside, research analysts plainly believe Bausch Health Companies is more favorable than Merus.
Bausch Health Companies has a net margin of -5.07% compared to Bausch Health Companies' net margin of -390.36%. Bausch Health Companies' return on equity of -44.13% beat Merus' return on equity.
Bausch Health Companies has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Bausch Health Companies received 26 more outperform votes than Merus when rated by MarketBeat users. However, 65.52% of users gave Merus an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
Summary
Merus beats Bausch Health Companies on 10 of the 18 factors compared between the two stocks.
Get Merus News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
